

## International Conference on gee Obesity and Weight Loss

November 6-8, 2017 Barcelona, Spain

## My New Gut: Insulin Resistance-Linking Modulation of the Gut Micro Biome to Dietary Recommendations and Health Claims

Stoffer Loman and Jan Willem van der Kamp NutriClaim, Netherlands

besity is one of the greatest public health challenges of the 21st century. Its prevalence has tripled in many countries of the World Health Organization (WHO) European Region since the 1980s, and the numbers of those affected continue to rise at an alarming rate. In addition to causing various physical disabilities and psychological problems, excess weight drastically increases a person's risk of developing a number of non-communicable diseases), including cardiovascular disease, cancer and diabetes. Worldwide, current dietary recommendations don't refer to the role of the gut microbiome in health. Nevertheless, from a public health perspective, establishment of a physiologically relevant, beneficial health effect following modification of the microbiome on obesity should best be established by the favourable modification of one common denominator that is directly linked to a physiological beneficial effect. As common denominator of studies into the dietary modulation of the microbiome by probiotic and prebiotic foods, 'insulin resistance' has been proposed. Not only is insulin resistance a hallmark in the development of obesity and type 2 diabetes, but it is also implicated in a plethora of disease states and diseases associated with metabolic syndrome, like excessive weight, hypertension, atherogenic dyslipidemia and chronic low-grade inflammation. This notion implies that insulin resistance should be one of the important, if not the most important primary outcome measure in clinical studies, applying pre- and probiotic interventions and performed in the context of applied microbiome research. Taken together, in order to make the shift from microbiome research towards its application in dietary strategies and recommendations, as well as into health claims made on newly developed microbiome-modifying foods, we hypothesize that microbiome research should, at least in part, be targeted at deciphering the impact of (un)favourable modulation of the micro biome on insulin resistance.

## **Biography:**

Stoffer has acquired a BSc-degree in Tropical Agriculture at the Royal Dutch College for Tropical Agriculture Deventer, the Netherlands, was trained a Nutritionist (MSc) at Wageningen University (1992) and has obtained his PhD in Medical Sciences/Immunology at the Academic Medical Centre of the University of Amsterdam/ (1998). Following a career in the food supplement industry as science communicator and health educator he founded NutriClaim in 2007 (<a href="www.nutriclaim.com">www.nutriclaim.com</a>), providing specialist services pertaining to the scientific substantiation of health claims made on food, and in the marketing authorization of Novel Foods in the EU. Currently, Stoffer is also Work Package Leader in the EU FP7-funded project "My New Gut".